Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian Collins

Showing results (1-10 of 103) with videos related to

Pageof 11
Sort By:
Anti-Cancer Agents in Medicinal Chemistry|January 20, 2009
Targeted small-molecule inhibitors of protein kinase B as anticancer agentsIan Collins
Expert Opinion on Therapeutic Patents|May 24, 2011
Checkpoint kinase inhibitors: a patent review (2009 - 2010)Michael Lainchbury, Ian Collins
Chemistry & Biology|July 9, 2010
Probing the probes: fitness factors for small molecule toolsPaul Workman, Ian Collins
Future Medicinal Chemistry|August 4, 2012
Macrocycles in new drug discoveryJamie Mallinson, Ian Collins
Nature Chemical Biology|November 17, 2006
New approaches to molecular cancer therapeuticsIan Collins, Paul Workman
Future Medicinal Chemistry|February 17, 2015
Photoaffinity labeling in target- and binding-site identificationEwan Smith, Ian Collins
Future Medicinal Chemistry|July 9, 2019
Labelled chemical probes for demonstrating direct target engagement in living systemsHugues Prevet, Ian Collins
Trends in Pharmacological Sciences|April 5, 2011
Anticancer therapy with checkpoint inhibitors: what, where and when?Michelle D Garrett, Ian Collins
Current Opinion in Pharmacology|June 21, 2005
Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitorsIan Collins, Michelle D Garrett
Journal of Natural Products|October 6, 2011
The 2,11-cyclized cembranoids: cladiellins, asbestinins, and briarellins (period 1998-2010)Amanda J Welford, Ian Collins
Pageof 11

Showing results (1-10 of 103) with videos related to

Sort By:
Pageof 11
Anti-Cancer Agents in Medicinal Chemistry|January 20, 2009
Targeted small-molecule inhibitors of protein kinase B as anticancer agentsIan Collins
Expert Opinion on Therapeutic Patents|May 24, 2011
Checkpoint kinase inhibitors: a patent review (2009 - 2010)Michael Lainchbury, Ian Collins
Chemistry & Biology|July 9, 2010
Probing the probes: fitness factors for small molecule toolsPaul Workman, Ian Collins
Future Medicinal Chemistry|August 4, 2012
Macrocycles in new drug discoveryJamie Mallinson, Ian Collins
Nature Chemical Biology|November 17, 2006
New approaches to molecular cancer therapeuticsIan Collins, Paul Workman
Future Medicinal Chemistry|February 17, 2015
Photoaffinity labeling in target- and binding-site identificationEwan Smith, Ian Collins
Future Medicinal Chemistry|July 9, 2019
Labelled chemical probes for demonstrating direct target engagement in living systemsHugues Prevet, Ian Collins
Trends in Pharmacological Sciences|April 5, 2011
Anticancer therapy with checkpoint inhibitors: what, where and when?Michelle D Garrett, Ian Collins
Current Opinion in Pharmacology|June 21, 2005
Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitorsIan Collins, Michelle D Garrett
Journal of Natural Products|October 6, 2011
The 2,11-cyclized cembranoids: cladiellins, asbestinins, and briarellins (period 1998-2010)Amanda J Welford, Ian Collins
Pageof 11